Notably, specifically for the HRpos/HER2neg BC patient population, for whom pCR might not be the optimal predictor of outcome, the CPS + EG score (including pre‐treatment clinical stage, post‐treatment pathological stage, ER status and tumor grade) has been suggested as a valuable alternative. The gene discussed is ESR1; the disease is neoplasm.